Cisatracurium Besylate (Cisatracurium Besylate) Patent Expiration, LOE Window & CMS Spending

Cisatracurium Besylate (Cisatracurium Besylate) by Sandoz: Multi-Source Generic Molecule, 2 AB generics, $2K 2024 CMS Part D & Medicaid spend, and $940 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSandoz
FDA Application & PathwayReconciled (ANDA)
Exclusivity / Cliff HorizonMulti-Source Generic Molecule
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors2
2024 CMS Total Public Spend$2K
2024 Medicare Part D Spend$0
2024 Medicaid Spend$2K
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($940 intro WAC)